Dasatinib plus ropeginterferon for new CML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two drugs, dasatinib and ropeginterferon, for people newly diagnosed with chronic myeloid leukemia (CML) in its early chronic phase. The goal is to see if the combination works safely and helps control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have Philadelphia chromosome-positive or BCR::ABL1-positive CML in chronic phase (the early stage of CML).
- You can have had brief prior treatment with hydroxyurea, up to 2 doses of cytarabine, or a TKI (like imatinib) for less than 30 days.
- You are in good overall health (ECOG performance status 0-2) and have adequate liver and kidney function.
- You agree to use effective birth control if you or your partner could become pregnant.
- You do not have serious heart disease, uncontrolled depression, active autoimmune disease, or active infections that are not under control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
This trial tests the drug olverembatinib alone for people with newly diagnosed chronic phase CML who have not had much prior treatment. It aims to see how well the drug works and what side effects it may cause.
This trial studies a new drug (KRT-232) combined with a standard CML “TKI” medicine to treat chronic myeloid leukemia (CML) that is resistant or not tolerated after at least one prior TKI. It may help people whose leukemia hasn’t controlled as expected on current treatments.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
This trial tests a new combination of three drugs (a third-generation TKI, azacitidine, and a Bcl-2 inhibitor) for people with chronic myeloid leukemia that has progressed to a more advanced phase (myeloid blast phase). The goal is to see if this combination is safe and effective.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.